{
    "name": "bismuth subsalicylate",
    "comment": "OTC",
    "other_names": [
        "Kaopectate",
        "Pepto Bismol",
        "Maalox Total Relief",
        "Kaopectate Extra Strength",
        "Pepto-Bismol Maximum Strength"
    ],
    "classes": [
        "Antidiarrheals",
        "H pylori Agents"
    ],
    "source": "https://reference.medscape.com/drug/kaopectate-pepto-bismol-bismuth-subsalicylate-342037",
    "pregnancy": {
        "common": [
            "Pregnancy category: C; D in 3rd trimester",
            "Lactation: Salicylates enter breast milk; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Salicylates enter breast milk; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to bismuth, aspirin, other salicylates",
                "Infectious diarrhea, high fever, von Willebrand disease, hemorrhage, ulcer or GI bleeding with black or bloody stool, hemophilia",
                "In pediatric patients, chicken pox or influenza (risk of Reye syndrome)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Bismuth subcitrate potassium may cause temporary and harmless darkening of tongue and/or black stools, generally reversible within several days after treatment stopped; stool darkening should not be confused with melena",
                "Bismuth absorbs x-rays and may interfere with x-ray diagnostic procedures of gastrointestinal tract",
                "Cases of neurotoxicity associated with excessive doses of various bismuth-containing products reported; effects have been reversible with discontinuation of bismuth therapy",
                "Not to be administered to children or teenagers recovering from flu-like symptoms or chickenpox; increased incidence of Reye syndrome, associated with salicylate products"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide increases levels of bismuth subsalicylate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "bismuth subsalicylate decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxycycline",
            "description": {
                "common": "bismuth subsalicylate decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "bismuth subsalicylate, eluxadoline.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "minocycline",
            "description": {
                "common": "bismuth subsalicylate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "bismuth subsalicylate decreases levels of oxytetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetracycline",
            "description": {
                "common": "bismuth subsalicylate decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "warfarin",
            "description": {
                "common": "bismuth subsalicylate increases effects of warfarin by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "bismuth subsalicylate, acebutolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "bismuth subsalicylate, atenolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "bismuth subsalicylate decreases effects of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Salicylates may also increase nephrotoxic effects of ACE inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "bismuth subsalicylate, betaxolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bismuth subsalicylate, bisoprolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "bismuth subsalicylate, carvedilol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "bismuth subsalicylate, celiprolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "bismuth subsalicylate, esmolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "bismuth subsalicylate, labetalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "bismuth subsalicylate will decrease the level or effect of metoclopramide intranasal by  Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "bismuth subsalicylate, metoprolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "bismuth subsalicylate, nadolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "bismuth subsalicylate, nebivolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "bismuth subsalicylate will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "bismuth subsalicylate, penbutolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "bismuth subsalicylate, pindolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "bismuth subsalicylate, propranolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "bismuth subsalicylate will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "bismuth subsalicylate, sotalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "bismuth subsalicylate, timolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and bismuth subsalicylate both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin",
            "description": {
                "common": "bismuth subsalicylate increases effects of aspirin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "bismuth subsalicylate increases effects of aspirin rectal by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "bismuth subsalicylate increases effects of aspirin/citric acid/sodium bicarbonate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esomeprazole",
            "description": {
                "common": "esomeprazole increases levels of bismuth subsalicylate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "omeprazole",
            "description": {
                "common": "omeprazole increases levels of bismuth subsalicylate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "12"
        },
        {
            "name": "Diarrhea",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Melena",
            "percent": "3"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "2"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Anorexia",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": "2"
        },
        {
            "name": "Discolored tongue",
            "percent": "2"
        },
        {
            "name": "Headache",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Stool abnormality",
            "percent": "1"
        },
        {
            "name": "Duodenal ulcer",
            "percent": "1"
        },
        {
            "name": "Sinusitis",
            "percent": "1"
        },
        {
            "name": "Taste perversion",
            "percent": "1"
        },
        {
            "name": "Flatulence",
            "percent": "1"
        },
        {
            "name": "GI hemorrhage",
            "percent": "1"
        },
        {
            "name": "Pain",
            "percent": "1"
        },
        {
            "name": "Insomnia",
            "percent": "1"
        },
        {
            "name": "Anal discomfort",
            "percent": "1"
        },
        {
            "name": "Paresthesia",
            "percent": "1"
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "Weakness",
            "percent": null
        },
        {
            "name": "Gray",
            "percent": null
        },
        {
            "name": "black stool",
            "percent": null
        },
        {
            "name": "Impaction",
            "percent": null
        },
        {
            "name": "Muscle spasm",
            "percent": null
        },
        {
            "name": "Neurotoxicity",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        }
    ]
}